E-LIB Suche - Ergebnisse für: von Pawel, Joachim

1

Improvement of differential diagnosis of lung cancer by use..:

Trulson, Inga ; Klawonn, Frank ; von Pawel, Joachim...
Tumor Biology. 46 (2024) s1 - p. S81-S98 , 2024

Link: https://doi.org/10.3233/..

2

Lack of clinical utility of serum macrophage migration inhi..:

Rupp, Alexander ; Bahlmann, Sophie ; Trimpop, Nicolai...
Tumor Biology. 46 (2024) s1 - p. S341-S353 , 2024

Link: https://doi.org/10.3233/..

3

Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Bi..:

Handke, Nikolaus ; Rupp, Alexander ; Trimpop, Nicolai..
Diagnostics. 11 (2021) 2 - p. 356 , 2021

Link: https://doi.org/10.3390/..

4

Atezolizumab in patients with advanced non-small cell lung ..:

Gadgeel, Shirish M. ; Lukas, Rimas V. ; Goldschmidt, Jerome...
Lung Cancer. 128 (2019) - p. 105-112 , 2019

Link: https://doi.org/10.1016/..

5

Atezolizumab Treatment Beyond Progression in Advanced NSCLC..:

Gandara, David R. ; von Pawel, Joachim ; Mazieres, Julien...
Journal of Thoracic Oncology. 13 (2018) 12 - p. 1906-1918 , 2018

Link: https://doi.org/10.1016/..

6

Patient-Reported Outcomes in OAK: A Phase III Study of Atez..:

Bordoni, Rodolfo ; Ciardiello, Fortunato ; von Pawel, Joachim...
Clinical Lung Cancer. 19 (2018) 5 - p. 441-449.e4 , 2018

Link: https://doi.org/10.1016/..

7

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or P..:

von Pawel, Joachim ; Spigel, David R. ; Ervin, Thomas...
The Oncologist. 23 (2018) 6 - p. 654-e58 , 2018

Link: https://doi.org/10.1634/..

8

Metronomic treatment of advanced non-small-cell lung cancer..:

Guetz, Sylvia ; Tufman, Amanda ; von Pawel, Joachim...
OncoTargets and Therapy. 10 (2017) - p. 1081-1089 , 2017

Link: https://doi.org/10.2147/..

9

P3.02b-045 Patritumab plus Erlotinib in EGFR Wild-Type Adva..:

Paz-Arez, Luis ; Serwatowski, Piotr ; Szczęsna, Aleksandra...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S1214-S1215 , 2017

Link: https://doi.org/10.1016/..

10

Circulating heregulin level is associated with the efficacy..:

Yonesaka, Kimio ; Hirotani, Kenji ; von Pawel, Joachim...
Lung Cancer. 105 (2017) - p. 1-6 , 2017

Link: https://doi.org/10.1016/..

11

Efficacy and Safety of Nintedanib Plus Docetaxel in Patient..:

Gottfried, Maya ; Bennouna, Jaafar ; Bondarenko, Igor...
Targeted Oncology. 12 (2017) 4 - p. 475-485 , 2017

Link: https://doi.org/10.1007/..

12

PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs..:

Gadgeel, Shirish ; Ciardiello, Fortunato ; Rittmeyer, Achim...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S9-S10 , 2017

Link: https://doi.org/10.1016/..

13

Nintedanib plus pemetrexed versus placebo plus pemetrexed i..:

Hanna, Nasser H. ; Kaiser, Rolf ; Sullivan, Richard N....
Lung Cancer. 102 (2016) - p. 65-73 , 2016

Link: https://doi.org/10.1016/..

14

Editorial:

Jaehde, Ulrich ; Bendas, Gerd ; Sehrt, Daniel.
Int. Journal of Clinical Pharmacology and Therapeutics. 53 (2015) 12 - p. 1037 , 2015

Link: https://doi.org/10.5414/..

15

Analysis of patient-reported outcomes from the LUME-Lung 1 ..:

Novello, Silvia ; Kaiser, Rolf ; Mellemgaard, Anders...
European Journal of Cancer. 51 (2015) 3 - p. 317-326 , 2015

Link: https://doi.org/10.1016/..